» Articles » PMID: 15551191

The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry

Overview
Specialties Pharmacology
Psychiatry
Date 2004 Nov 20
PMID 15551191
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables the clinician to adjust the dosage of drugs according to the characteristics of the individual patient. In psychiatry, TDM is an established procedure for lithium, some antidepressants and antipsychotics. In spite of its obvious advantages, however, the use of TDM in everyday clinical practice is far from optimal. The interdisciplinary TDM group of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) has therefore worked out consensus guidelines to assist psychiatrists and laboratories involved in psychotropic drug analysis to optimise the use of TDM of psychotropic drugs. Five research-based levels of recommendation were defined with regard to routine monitoring of plasma concentrations for dose titration of 65 psychoactive drugs: (1) strongly recommended, (2) recommended, (3) useful, (4) probably useful and (5) not recommended. A second approach defined indications to use TDM, e. g. control of compliance, lack of clinical response or adverse effects at recommended doses, drug interactions, pharmacovigilance programs, presence of a genetic particularity concerning the drug metabolism, children, adolescents and elderly patients. Indications for TDM are relevant for all drugs either with or without validated therapeutic ranges. When studies on therapeutic ranges are lacking, target ranges should be plasma concentrations that are normally observed at therapeutic doses of the drug. Therapeutic ranges of plasma concentrations that are considered to be optimal for treatment are proposed for those drugs, for which the evaluation of the literature demonstrated strong evidence. Moreover, situations are defined when pharmacogenetic (phenotyping or genotyping) tests are informative in addition to TDM. Finally, practical instructions are given how to use TDM. They consider preparation of TDM, analytical procedures, reporting and interpretation of results and the use of information for patient treatment. Using the consensus guideline will help to ensure optimal clinical benefit of TDM in psychiatry.

Citing Articles

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?.

Guo H, Huang J, Wang J, Fan L, Li Y, Wu D Front Pharmacol. 2024; 15:1484512.

PMID: 39534083 PMC: 11554470. DOI: 10.3389/fphar.2024.1484512.


Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study.

Riegger J, Egberts K, Clement H, Schneider-Momm K, Taurines R, Fekete S J Neural Transm (Vienna). 2024; 132(2):295-312.

PMID: 39487894 PMC: 11785646. DOI: 10.1007/s00702-024-02819-6.


Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes.

Biso L, Aringhieri S, Carli M, Scarselli M, Longoni B Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794212 PMC: 11124530. DOI: 10.3390/ph17050642.


Distribution of quetiapine between serum and whole blood in therapeutic drug-monitoring specimens.

Breivik H, Tunset M, Schou M, Frost J J Anal Toxicol. 2024; 48(3):180-184.

PMID: 38407283 PMC: 10977622. DOI: 10.1093/jat/bkae006.


Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument.

Yi Z, Li X, Wang Z, Qin J, Jiang D, Tian P Clin Pharmacokinet. 2023; 62(9):1201-1217.

PMID: 37490190 DOI: 10.1007/s40262-023-01283-x.